|||
Our approach prioritizes:
grounded in first principles.
Our rule-based systems offer transparent, regulation-ready models that don’t require vast datasets or lengthy validation cycles. Unlike data-intensive AI approaches, our models are built on deterministic insights rooted in physiology (Learn more about Therapeutic Areas).
Foundational Rule-Based AI
With a streamlined approach, our modeling and simulation (M&S) methods reduce development timelines, delivering actionable insights faster to enable quicker time-to-market for digital health solutions.
Our AI-driven disease models, digital twins, and digital biomarkers serve as the backbone for innovation in both Digital Therapeutics (DTx) R&D and Smart Medications. By leveraging these tools, we enable a shift from generalized, ‘average patient’ treatments to highly personalized digital therapies, accelerating development while enhancing clinical outcomes.
Our in silico platform with virtual patient populations provides a dynamic foundation that bridges standard care with patient-specific interventions, enabling faster, more precise decision-making and setting a new standard for tailored digital health solutions.
In Silico Platform
Example of Migraine Forecast Biomaker Validation Scheme
From Molecule to Human Behavior: A Systems Medicine Approach
